Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.
Authors
Kuaile Zhao
Department of Radiation Oncology, Fudan Cancer Hospital, Shanghai, China
Kuaile Zhao , Sung-Bae Kim , Ken Kato , Chih-Hung Hsu , Sheng Hu , Feng Wang , Takashi Kojima , Young Saing Kim , Eric Van Cutsem , Jaffer A. Ajani , Liyun Li , Ningning Ding , Aiyang Tao , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03430843
DOI
10.1200/JCO.2022.40.4_suppl.279
Abstract #
279
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
First Author: Eric Van Cutsem
Poster
2021 ASCO Annual Meeting
RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
First Author: Lin Shen
Poster
2021 Gastrointestinal Cancers Symposium
Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.
First Author: Keisho Chin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
First Author: Eric Raymond